Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 47.2% in January

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 91,400 shares, a drop of 47.2% from the January 15th total of 173,000 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 101,300 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Brainstorm Cell Therapeutics in a research report on Friday. They issued a “hold” rating for the company.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock traded up $0.06 during midday trading on Friday, reaching $1.86. 30,653 shares of the company were exchanged, compared to its average volume of 55,534. The company has a market capitalization of $10.60 million, a price-to-earnings ratio of -0.39 and a beta of 0.26. The firm’s 50-day simple moving average is $1.99 and its 200-day simple moving average is $2.67. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.